HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NERV
Minerva Neurosciences, Inc.
There isn't enough reported data to score NERV yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NERV Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Unavailable | |
| Strong |
NERV's balance sheet is currently strong, but its revenue and profitability are weak. There isn't enough data to rate its cash flow.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NERV PE Valuation
NERV has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NERV Forward outlook
There aren't enough analyst estimates for NERV to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has the edge over NERV on earnings, with more consistent year-over-year improvement.
NERV Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$36.57 | -$34.72 |
| Q2 2026 | -$36.74 | -2582% |
| Q1 2026 | -$37.03 | -4616% |
| Q4 2025 | -$34.67 | -18347% |
| Q3 2025 | -$1.85 | -$1.45 |
| Q2 2025 | $1.48 | +$5.88 |
| Q1 2025 | $0.82 | +$5.25 |
| Q4 2024 | $0.19 | +$4.80 |
NERV lost $36.57 per share over the past year, a bigger loss than the year before.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
NERV Quarterly Revenue
NERV's revenue has slid since its 2020 peak: $0 last quarter.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2020 | 72% | N/A |
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NERV on cash generation, producing positive trailing cash flow while its opponent burns cash.
NERV Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$8.1M | -$5.2M |
| Q2 2026 | -$13.3M | -$11.3M |
| Q1 2026 | -$5.4M | -$1.4M |
| Q4 2025 | -$4.5M | +$686K |
| Q3 2025 | -$2.9M | +$1.4M |
| Q2 2025 | -$2M | +$1.9M |
| Q1 2025 | -$4.1M | +$2M |
| Q4 2024 | -$5.2M | +$824.6K |
NERV has burned cash in almost every quarter: −$31M over the past year, against −$14M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NERV on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NERV Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -4.9% | -3.9M shares |
| 1 year | +894% | +67.7M shares |
| 3 years | +894% | +67.7M shares |
| 5 years | +1309% | +69.9M shares |
| Available history | +1443% | +70.4M shares |
NERV has 75M diluted shares, up 894% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NERV Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2020 | -13.6x | Net Cash |
NERV has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NERV Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 11.3 | Oversold |
NERV's weekly RSI is 31 (neutral) and its Stochastic is 11 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NERV PE vs Healthcare Sector
| Metric | NERV | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
NERV has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NERV Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.70 | 12% below |
| 20 week MA | $3.73 | 36% below |
| 50 week MA | $4.65 | 49% below |
| 100 week MA | $3.42 | 30% below |
| 200 week MA | $4.02 | 41% below |
NERV is in a downtrend: it's below all five of its weekly moving averages, and 41% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over NERV on returns for 2026, with the stronger performance.
NERV Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $54.2 | $19.7 | -64% |
| 2021 | $19.7 | $7.72 | -61% |
| 2022 | $7.72 | $2.48 | -68% |
| 2023 | $2.48 | $6.15 | +148% |
| 2024 | $6.15 | $2.26 | -63% |
| 2025 | $2.26 | $4.19 | +85% |
| 2026 YTD | $4.19 | $2.38 | -43% |
NERV's yearly returns have swung widely, from +148% in 2023 to −68% in 2022. It's down 43% so far in 2026.